ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Johnson & Johnson will eliminate about 900 positions in its Ortho-McNeil-Janssen Pharmaceuticals division. The cutbacks, which will mainly affect U.S. salespeople, represent about 6% of the division's staff. Meanwhile, Amgen will consolidate its clinical manufacturing operations in Thousand Oaks, Calif., eliminating 100 positions at a facility in Bothell, Wash. The Bothell facility, which came with Amgen's 2002 acquisition of Immunex, will continue to house oncology research in conjunction with a center in Seattle.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter